4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.63), $0.05 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $1.27 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.